Sanofi Form 6-K April 25, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2012

Commission File Number: 001-31368

SANOFI

(Translation of registrant s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

	In	dicate	by	check	c mark	whe	ther	the:	registran	t files	or v	will	file	annual	reports	under	cove	r Form	20-F	or	Form -	40-	·F.
--	----	--------	----	-------	--------	-----	------	------	-----------	---------	------	------	------	--------	---------	-------	------	--------	------	----	--------	-----	-----

Form 20-F x Form 40-F "

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): "

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): "

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes " No x

If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In April 2012, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit List

Exhibit

No. Description

Exhibit 99.1 Press release dated April 24, 2012: Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada^{TM*} (Alemtuzumab) Compared With Rebif[®] in Phase Ill Trial

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: April 25, 2012 SANOFI

By /S/ John Felitti Name: John Felitti

Title: Associate Vice President, Corporate Law, Financial &

Securities Law

3

Exhibit Index

Exhibit

No. Description

Exhibit 99.1 Press release dated 24, 2012: Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received Lemtrada^{TM*} (Alemtuzumab) Compared With Rebif[®] in Phase Ill Trial

4